Logo image of SCLX

SCILEX HOLDING CO (SCLX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SCLX - US80880W2052 - Common Stock

16.63 USD
-0.17 (-1.01%)
Last: 12/12/2025, 8:01:32 PM
16.96 USD
+0.33 (+1.98%)
After Hours: 12/12/2025, 8:01:32 PM
Fundamental Rating

1

Taking everything into account, SCLX scores 1 out of 10 in our fundamental rating. SCLX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCLX have multiple concerns. SCLX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCLX has reported negative net income.
SCLX had a negative operating cash flow in the past year.
In the past 5 years SCLX reported 4 times negative net income.
In the past 5 years SCLX always reported negative operating cash flow.
SCLX Yearly Net Income VS EBIT VS OCF VS FCFSCLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

SCLX has a worse Return On Assets (-164.82%) than 89.01% of its industry peers.
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROIC N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCLX Yearly ROA, ROE, ROICSCLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 100 -100 200

1.3 Margins

Looking at the Gross Margin, with a value of 66.45%, SCLX is in the better half of the industry, outperforming 75.39% of the companies in the same industry.
SCLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCLX Yearly Profit, Operating, Gross MarginsSCLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

SCLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SCLX Yearly Shares OutstandingSCLX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M
SCLX Yearly Total Debt VS Total AssetsSCLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SCLX has an Altman-Z score of -11.88. This is a bad value and indicates that SCLX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SCLX (-11.88) is worse than 77.49% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.88
ROIC/WACCN/A
WACC8.98%
SCLX Yearly LT Debt VS Equity VS FCFSCLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

SCLX has a Current Ratio of 0.19. This is a bad value and indicates that SCLX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.19, SCLX is doing worse than 95.29% of the companies in the same industry.
A Quick Ratio of 0.17 indicates that SCLX may have some problems paying its short term obligations.
SCLX has a Quick ratio of 0.17. This is amonst the worse of the industry: SCLX underperforms 94.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.17
SCLX Yearly Current Assets VS Current LiabilitesSCLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.85%

3.2 Future

SCLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.57% yearly.
SCLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.38% yearly.
EPS Next Y-64.81%
EPS Next 2Y46.84%
EPS Next 3Y32.54%
EPS Next 5Y20.57%
Revenue Next Year-34%
Revenue Next 2Y136.81%
Revenue Next 3Y108.2%
Revenue Next 5Y75.38%

3.3 Evolution

SCLX Yearly Revenue VS EstimatesSCLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SCLX Yearly EPS VS EstimatesSCLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SCLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SCLX is valuated cheaply with a Price/Forward Earnings ratio of 5.24.
Based on the Price/Forward Earnings ratio, SCLX is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
SCLX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.79.
Industry RankSector Rank
PE N/A
Fwd PE 5.24
SCLX Price Earnings VS Forward Price EarningsSCLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCLX Per share dataSCLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

SCLX's earnings are expected to grow with 32.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.84%
EPS Next 3Y32.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCLX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SCILEX HOLDING CO

NASDAQ:SCLX (12/12/2025, 8:01:32 PM)

After market: 16.96 +0.33 (+1.98%)

16.63

-0.17 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-30 2026-03-30/bmo
Inst Owners9.93%
Inst Owner Change-4.41%
Ins Owners0.32%
Ins Owner Change0%
Market Cap126.22M
Revenue(TTM)N/A
Net Income(TTM)-166.98M
Analysts43.33
Price Target499.8 (2905.41%)
Short Float %4.45%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.24%
Min EPS beat(2)-256.34%
Max EPS beat(2)-8.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-19.06%
Max Revenue beat(2)15.44%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.24
P/S 2.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.3
EYN/A
EPS(NY)3.17
Fwd EY19.08%
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS6.16
BVpS-22.78
TBVpS-29.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.45%
FCFM N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.96%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.17
Altman-Z -11.88
F-Score2
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)20.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-64.81%
EPS Next 2Y46.84%
EPS Next 3Y32.54%
EPS Next 5Y20.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.85%
Revenue Next Year-34%
Revenue Next 2Y136.81%
Revenue Next 3Y108.2%
Revenue Next 5Y75.38%
EBIT growth 1Y-375.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.59%
OCF growth 3YN/A
OCF growth 5YN/A

SCILEX HOLDING CO / SCLX FAQ

Can you provide the ChartMill fundamental rating for SCILEX HOLDING CO?

ChartMill assigns a fundamental rating of 1 / 10 to SCLX.


What is the valuation status for SCLX stock?

ChartMill assigns a valuation rating of 3 / 10 to SCILEX HOLDING CO (SCLX). This can be considered as Overvalued.


Can you provide the profitability details for SCILEX HOLDING CO?

SCILEX HOLDING CO (SCLX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SCILEX HOLDING CO?

The Earnings per Share (EPS) of SCILEX HOLDING CO (SCLX) is expected to decline by -64.81% in the next year.